New agents for treatment of children with acute myelogenous leukemia

Robert J. Wells, Carola A.S. Arndt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Over the past 15 years, daunorubicin, cytosine arabinoside and, to a lesser extent, 6-thioguanine and etoposide have become the standard agents used to treat patients with acute myelogenous leukemia (AML). These agents have been used in various combinations and schedules with only small improvements in overall outcome because few other agents with promise were available. This situation has changed over the past few years so that today there are a number of new agents that have the potential to supplement or replace the standard drugs. Idarubicin, mitoxantrone, amsacrine, homoharringtonine, 2-chlorodeoxyadenosine, fludarabine, carboplatin, retinoids, colony stimulating factors, and interleukin-2 are discussed.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume17
Issue number3
StatePublished - 1995

Fingerprint

Acute Myeloid Leukemia
Amsacrine
Idarubicin
Cladribine
Thioguanine
Mitoxantrone
Daunorubicin
Carboplatin
Cytarabine
Retinoids
Etoposide
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-2
Appointments and Schedules
Therapeutics
Pharmaceutical Preparations
homoharringtonine
fludarabine

Keywords

  • 2-chloradeoxyadenosine
  • Carboplatin
  • Fludarabine
  • Idarubicin
  • Mitoxantrone

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

New agents for treatment of children with acute myelogenous leukemia. / Wells, Robert J.; Arndt, Carola A.S.

In: Journal of Pediatric Hematology/Oncology, Vol. 17, No. 3, 1995, p. 225-233.

Research output: Contribution to journalArticle

@article{5b84923f31c24da483b48ec41ed35a50,
title = "New agents for treatment of children with acute myelogenous leukemia",
abstract = "Over the past 15 years, daunorubicin, cytosine arabinoside and, to a lesser extent, 6-thioguanine and etoposide have become the standard agents used to treat patients with acute myelogenous leukemia (AML). These agents have been used in various combinations and schedules with only small improvements in overall outcome because few other agents with promise were available. This situation has changed over the past few years so that today there are a number of new agents that have the potential to supplement or replace the standard drugs. Idarubicin, mitoxantrone, amsacrine, homoharringtonine, 2-chlorodeoxyadenosine, fludarabine, carboplatin, retinoids, colony stimulating factors, and interleukin-2 are discussed.",
keywords = "2-chloradeoxyadenosine, Carboplatin, Fludarabine, Idarubicin, Mitoxantrone",
author = "Wells, {Robert J.} and Arndt, {Carola A.S.}",
year = "1995",
language = "English (US)",
volume = "17",
pages = "225--233",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - New agents for treatment of children with acute myelogenous leukemia

AU - Wells, Robert J.

AU - Arndt, Carola A.S.

PY - 1995

Y1 - 1995

N2 - Over the past 15 years, daunorubicin, cytosine arabinoside and, to a lesser extent, 6-thioguanine and etoposide have become the standard agents used to treat patients with acute myelogenous leukemia (AML). These agents have been used in various combinations and schedules with only small improvements in overall outcome because few other agents with promise were available. This situation has changed over the past few years so that today there are a number of new agents that have the potential to supplement or replace the standard drugs. Idarubicin, mitoxantrone, amsacrine, homoharringtonine, 2-chlorodeoxyadenosine, fludarabine, carboplatin, retinoids, colony stimulating factors, and interleukin-2 are discussed.

AB - Over the past 15 years, daunorubicin, cytosine arabinoside and, to a lesser extent, 6-thioguanine and etoposide have become the standard agents used to treat patients with acute myelogenous leukemia (AML). These agents have been used in various combinations and schedules with only small improvements in overall outcome because few other agents with promise were available. This situation has changed over the past few years so that today there are a number of new agents that have the potential to supplement or replace the standard drugs. Idarubicin, mitoxantrone, amsacrine, homoharringtonine, 2-chlorodeoxyadenosine, fludarabine, carboplatin, retinoids, colony stimulating factors, and interleukin-2 are discussed.

KW - 2-chloradeoxyadenosine

KW - Carboplatin

KW - Fludarabine

KW - Idarubicin

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=0029154062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029154062&partnerID=8YFLogxK

M3 - Article

C2 - 7620921

AN - SCOPUS:0029154062

VL - 17

SP - 225

EP - 233

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -